key: cord-0739141-7fymv4oh
authors: Lepper, Philipp M; Langer, Frank; Wilkens, Heinrike; Schäfers, Hans-Joachim; Bals, Robert
title: Lung transplantation for COVID-19-associated ARDS
date: 2021-07-02
journal: Lancet Respir Med
DOI: 10.1016/s2213-2600(21)00278-2
sha: 0320f72b18b56692be08caee0223312fba6a9e3a
doc_id: 739141
cord_uid: 7fymv4oh

nan

We read with interest the study in The Lancet Respiratory Medicine by Ankit Bharat and colleagues, 1 regarding a case series of patients with COVID-19-associated acute respiratory distress syndrome (ARDS) who were bridged to lung transplantation by extracorporeal membrane oxygenation (ECMO). COVID-19 has affected millions of patients, some of whom will develop ARDS 2 and some of whom will die. Bridging of patients to lung transplantation with ECMO is being used increasingly with growing success. 3 Bharat and colleagues carry the concept further and propose a more liberal use of transplantation for COVID-19-associated ARDS. This approach raises medical issues. Some criteria can help in decision making over whether a patient with ARDS is suitable for transplantation. Good potential for recovery, thorough evaluation before transplantation, single organ failure, and informed consent are required to ensure high success rates. In Bharat and colleagues' case series, 1 patients did not necessarily meet these requirements. As expected, the patients had a complicated intraoperative and postoperative course (eg, mass transfusion, continued extracorporeal support, re-thoracotomy, primary graft dysfunction, and prolonged postoperative stay in the intensive care unit [ICU]). The success of a transplantation procedure cannot solely be judged by the fact that a patient can be discharged from the ICU. At least a year, if not longer, is required before such a procedure should be considered successful. Furthermore, there is an ethical dilemma. Transplantation for irreversible pulmonary disease is characterised by a global shortage of donor organs. Patients with a good prognosis can die on the waiting list. 4 Consequently, recipients should be carefully selected. The organ shortage is not relieved but rather aggravated by the COVID-19 pandemic. Accepting high-urgency candidates with ARDS during the pandemic will disadvantage patients on the waiting list, increase waiting-list mortality, decrease posttransplantation survival, 5 and distort the discriminatory capacity of any organ allocation systems. Around 600 patients are listed for lung transplantation in the Eurotransplant region. At most, 1% of these patients has a lung allocation score (LAS) of 85 and above, thus the reported patients 1 will outperform 99% of patients on the current waiting list. At our centre alone, we identified five patients who fulfilled the criteria mentioned by the authors. These issues should be considered carefully, as this could skew allocation systems tremendously. Given the high mortality of patients with COVID-19 on ECMO, we agree with the authors that lung transplantation should be considered an option; however, we suggest to set the LAS to 0 by default for patients with COVID-19-associated ARDS, thereby allowing rescue allocation for transplantation only.

HW reports consulting fees from Actelion, Bayer, and Janssen; and speaker's fees from Actelion, Bayer, Biotest, Boehringer Ingelheim, Janssen, MSD, Pfizer, and Roche, outside the submitted work. RB received research funding from the German Center for Lung Research (Deutsches Zentrum für Lungenforschung) for the COPD and SYstemic consequences-COmorbidities NETwork (COSYCONET; grant number 82DZLI05A2) cohort study, and from the German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF; grant number 01GI0881); and grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, and Novartis, during the preparation of this Correspondence. RB reports grants from BMBF for the Competence Network on Asthma and COPD (AsCoNet) and from Sander-Stiftung, Krebshilfe, and Mukoviszidose e.V.; grants and personal fees from AstraZeneca, Boehringer Ingelheim, and Novartis; and personal fees from CSL Behring, GlaxoSmithKline, and Grifols, outside the submitted work. All other authors declare no competing interests.

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study

Improving outcomes in bridge-to-transplant: extended extracorporeal membrane oxygenation support to obtain optimal donor lungs for marginal recipients

Lung transplantation in Germany since the introduction of the lung allocation score

High emergency organ allocation rule in lung transplantation: a simulation study

Hop Foch/Phanie/SPL